Scale is working, but policy can bite
- In Q1 2026, Diagnostic Information Services made up 97.8% of net revenue.
- New Corewell and Fresenius work added about 7% to organic requisition volume growth in Q1 2026.
- The court win on LDT rules removed a major near-term threat to advanced testing.
- The OBBBA law could cut consolidated revenue by 50 to 60 basis points by 2028.
- The stock looks balanced, not cheap, with Finn scoring it near the middle overall.
Bigger contracts, smaller rule risk
Quest is a scale story in medical testing. Doctors, hospitals, employers, and consumers send samples to Quest. Quest runs the tests, reports the results, and gets paid by health plans, government programs, hospitals, employers, or patients.
The bull case improved because a court vacated the FDA rule for Laboratory Developed Tests, or LDTs. These are tests built and used inside a lab. That matters because Quest wants Advanced Diagnostics, such as cancer and genetics tests, to grow faster and carry better margins.
The operating story also looks better. In Q1 2026, DIS revenue rose 9.4%, and organic requisition volume rose 10.8%. About 7% of that organic volume growth came from the new Corewell Health relationship and more testing for Fresenius Medical Care dialysis clinics.
The bear case is still real. Large hospital and dialysis work can bring lower revenue per requisition, even if it adds volume. At the same time, OBBBA could reduce consolidated revenue by 50 to 60 basis points by 2028, and PAMA reimbursement cuts remain an open policy risk.
Paid per test, helped by scale
Quest makes most of its money by performing lab tests. A requisition is the order that travels with a patient sample and tells Quest which tests to run and who should be billed. Revenue depends on how many requisitions Quest gets and how much it earns per requisition.
The main business is Diagnostic Information Services. In Q1 2026, it was 97.8% of net revenue. The smaller Diagnostic Solutions group was 2.2% and includes risk assessment services for insurers and healthcare technology businesses.
Scale is the key advantage. More volume can help Quest spread lab, logistics, technology, and billing costs over more tests. The Invigorate program is meant to deliver 3% annual cost savings and productivity gains, using automation and artificial intelligence in areas such as patient services, logistics, lab work, revenue services, IT, and procurement.
The model breaks when price, mix, or execution moves the wrong way. Government fee schedules, payer pressure, and big lower-priced contracts can hurt revenue per requisition. IT outages, acquisition problems, or a messy Project Nova rollout could also slow the business.
Routine tests fund harder tests
Routine clinical testing
This is the core testing work ordered by doctors and hospitals. It supplies the volume that makes Quest's network valuable.
Hospital lab services
Quest is winning more work from hospitals that need lower costs and help with lab staffing. Corewell Health and Fresenius are the key contracts to watch.
Advanced Diagnostics
This includes brain health, women's health, genetic, molecular, oncology, and cardiometabolic tests. The LDT court ruling lowered the near-term rule risk for this higher-value area.
Haystack MRD
Haystack MRD is aimed at finding minimal residual disease, which can signal cancer recurrence. Its revenue ramp is a key catalyst but still needs market adoption.
questhealth.com
This is Quest's consumer-initiated testing platform. It is smaller than the doctor and hospital channels, but it gives Quest a way to reach patients directly.
Employer services
This includes drug testing and population health services. It had been a drag, but management said the related businesses stabilized and returned to revenue growth in Q2 2025.
One main engine
The segment mix is from Quest's Q1 2026 Form 10-Q. Quest reports revenue mainly as Diagnostic Information Services and Diagnostic Solutions, while also managing customer channels such as physicians, hospitals, consumers, and employers.
What can go wrong
OBBBA revenue drag
Medium impact · High oddsQuest says OBBBA and the planned expiration of enhanced premium tax credits could reduce consolidated revenue by up to 50 to 60 basis points by 2028 compared with 2025. The hit is tied mainly to ACA Exchange Plan revenue. This is not a sudden cliff, but it can slow growth.
PAMA reimbursement cuts
High impact · Medium oddsPAMA affects what Medicare pays for many lab tests. If Congress does not delay or fix the cuts, Quest could face direct price pressure. That would matter because lab testing has high fixed costs and price cuts can flow through to margins.
Low-price volume mix
Medium impact · Medium oddsLarge contracts can add a lot of volume but may carry lower revenue per requisition. In Q1 2026, revenue per requisition fell 1.3% while requisition volume rose 10.9%. Quest needs scale benefits and advanced testing growth to offset that mix pressure.
Acquisition and venture integration
Medium impact · Medium oddsQuest is integrating recent deals and partnerships, including LifeLabs, Spectra, and Corewell Health. The Corewell venture is 51% owned by Quest and 49% owned by Corewell, with a new Michigan lab planned to be operational during 2027. Delays or cost overruns could reduce the benefit of the deal.
IT and Project Nova execution
Medium impact · Medium oddsQuest depends on technology for orders, logistics, billing, and results. The company is also running a multi-year IT modernization effort called Project Nova. A system outage or poor rollout could hurt service levels and cash collection.
Future LDT legislation
Medium impact · Low oddsA court vacated the FDA's LDT rule, and the FDA did not appeal. That removed the immediate threat. Congress could still try to pass a new law for LDT oversight, which would bring back uncertainty for Advanced Diagnostics.
In one breath
What does Quest Diagnostics do?
Quest runs lab tests on patient samples and sends results back to doctors, hospitals, patients, and other healthcare customers. Its main business is Diagnostic Information Services.
Why does the LDT ruling matter for Quest?
LDTs are tests developed and used inside a lab. A court vacated the FDA's LDT rule in March 2025, which reduced near-term regulatory risk for Quest's Advanced Diagnostics business.
Is Quest Diagnostics mainly a growth stock?
Quest has growth drivers, such as hospital partnerships and advanced tests, but it is also a mature healthcare services company. Finn's view is balanced because policy risk, pricing pressure, and valuation still matter.